A comparison study of HER2 protein overexpression and its gene status in breast cancer

Suria Hayati Md Pauzi, H. N. Saari, M. R. Roslan, S. N.S. Syed Khair Azman Jamalulil, I. S. Tauan, F. A. Mohd Rusli, A. N. Aizuddin

Research output: Contribution to journalArticle

Abstract

INTRODUCTION: Evaluation of HER2 status in breast cancer using immunohistochemistry (IHC) and in-situ-hybridisation (ISH) study is important to establish prognosis and to select patient for targeted therapy. OBJECTIVE: The study aims to determine the concordance between HER2 protein IHC score and its gene status by dual-colour dual-hapten in-situ-hybridization (DDISH) study. MATERIALS AND METHODS: Retrospective study was performed on 767 referred breast cancer cases over a period of five years. The HER2 IHC score (the initial and repeat test score) and the results of HER2 gene status by DDISH were retrieved from the histopathological reports. The agreement between initial IHC score with repeat test score was measured using Cohen Kappa. Chi square test analyzed the association between HER2 IHC score with its gene status by DDISH. RESULTS: The concordance of HER2 IHC score between the initial and repeat test were 52.7% and 89.4% for IHC score 2+ and 3+ respectively. There was moderate agreement of HER2 IHC score between the initial and repeat test score (ϰ = 0.526, p<0.001). A significant association noted between HER2 IHC score with its gene status by DDISH (p<0.001). Only 56 out of 207 cases (27.1%) with 2+ IHC score showed HER2 gene amplification while the majority of cases with 3+ IHC score were gene-amplified (446 out of 451, 98.9%). CONCLUSION: ISH study should be done in all IHC-equivocal cases (2+) to select patient for targeted therapy. Gene amplification must also be confirmed in IHC-positive cases (3+) to prevent from giving non-effective treatment with possible adverse effects to patient with non-amplified HER2 gene.

Original languageEnglish
Pages (from-to)133-138
Number of pages6
JournalThe Malaysian journal of pathology
Volume41
Issue number2
Publication statusPublished - 1 Aug 2019

Fingerprint

Immunohistochemistry
Breast Neoplasms
Genes
In Situ Hybridization
Proteins
Haptens
erbB-2 Genes
Color
Gene Amplification
Chi-Square Distribution
Therapeutics
Retrospective Studies

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Histology
  • Cell Biology

Cite this

Md Pauzi, S. H., Saari, H. N., Roslan, M. R., Syed Khair Azman Jamalulil, S. N. S., Tauan, I. S., Mohd Rusli, F. A., & Aizuddin, A. N. (2019). A comparison study of HER2 protein overexpression and its gene status in breast cancer. The Malaysian journal of pathology, 41(2), 133-138.

A comparison study of HER2 protein overexpression and its gene status in breast cancer. / Md Pauzi, Suria Hayati; Saari, H. N.; Roslan, M. R.; Syed Khair Azman Jamalulil, S. N.S.; Tauan, I. S.; Mohd Rusli, F. A.; Aizuddin, A. N.

In: The Malaysian journal of pathology, Vol. 41, No. 2, 01.08.2019, p. 133-138.

Research output: Contribution to journalArticle

Md Pauzi, SH, Saari, HN, Roslan, MR, Syed Khair Azman Jamalulil, SNS, Tauan, IS, Mohd Rusli, FA & Aizuddin, AN 2019, 'A comparison study of HER2 protein overexpression and its gene status in breast cancer', The Malaysian journal of pathology, vol. 41, no. 2, pp. 133-138.
Md Pauzi SH, Saari HN, Roslan MR, Syed Khair Azman Jamalulil SNS, Tauan IS, Mohd Rusli FA et al. A comparison study of HER2 protein overexpression and its gene status in breast cancer. The Malaysian journal of pathology. 2019 Aug 1;41(2):133-138.
Md Pauzi, Suria Hayati ; Saari, H. N. ; Roslan, M. R. ; Syed Khair Azman Jamalulil, S. N.S. ; Tauan, I. S. ; Mohd Rusli, F. A. ; Aizuddin, A. N. / A comparison study of HER2 protein overexpression and its gene status in breast cancer. In: The Malaysian journal of pathology. 2019 ; Vol. 41, No. 2. pp. 133-138.
@article{96b852a32e804a74bc83ee8e296e8aa3,
title = "A comparison study of HER2 protein overexpression and its gene status in breast cancer",
abstract = "INTRODUCTION: Evaluation of HER2 status in breast cancer using immunohistochemistry (IHC) and in-situ-hybridisation (ISH) study is important to establish prognosis and to select patient for targeted therapy. OBJECTIVE: The study aims to determine the concordance between HER2 protein IHC score and its gene status by dual-colour dual-hapten in-situ-hybridization (DDISH) study. MATERIALS AND METHODS: Retrospective study was performed on 767 referred breast cancer cases over a period of five years. The HER2 IHC score (the initial and repeat test score) and the results of HER2 gene status by DDISH were retrieved from the histopathological reports. The agreement between initial IHC score with repeat test score was measured using Cohen Kappa. Chi square test analyzed the association between HER2 IHC score with its gene status by DDISH. RESULTS: The concordance of HER2 IHC score between the initial and repeat test were 52.7{\%} and 89.4{\%} for IHC score 2+ and 3+ respectively. There was moderate agreement of HER2 IHC score between the initial and repeat test score (ϰ = 0.526, p<0.001). A significant association noted between HER2 IHC score with its gene status by DDISH (p<0.001). Only 56 out of 207 cases (27.1{\%}) with 2+ IHC score showed HER2 gene amplification while the majority of cases with 3+ IHC score were gene-amplified (446 out of 451, 98.9{\%}). CONCLUSION: ISH study should be done in all IHC-equivocal cases (2+) to select patient for targeted therapy. Gene amplification must also be confirmed in IHC-positive cases (3+) to prevent from giving non-effective treatment with possible adverse effects to patient with non-amplified HER2 gene.",
author = "{Md Pauzi}, {Suria Hayati} and Saari, {H. N.} and Roslan, {M. R.} and {Syed Khair Azman Jamalulil}, {S. N.S.} and Tauan, {I. S.} and {Mohd Rusli}, {F. A.} and Aizuddin, {A. N.}",
year = "2019",
month = "8",
day = "1",
language = "English",
volume = "41",
pages = "133--138",
journal = "Malaysian Journal of Pathology",
issn = "0126-8635",
publisher = "Malaysian Society of Pathologists",
number = "2",

}

TY - JOUR

T1 - A comparison study of HER2 protein overexpression and its gene status in breast cancer

AU - Md Pauzi, Suria Hayati

AU - Saari, H. N.

AU - Roslan, M. R.

AU - Syed Khair Azman Jamalulil, S. N.S.

AU - Tauan, I. S.

AU - Mohd Rusli, F. A.

AU - Aizuddin, A. N.

PY - 2019/8/1

Y1 - 2019/8/1

N2 - INTRODUCTION: Evaluation of HER2 status in breast cancer using immunohistochemistry (IHC) and in-situ-hybridisation (ISH) study is important to establish prognosis and to select patient for targeted therapy. OBJECTIVE: The study aims to determine the concordance between HER2 protein IHC score and its gene status by dual-colour dual-hapten in-situ-hybridization (DDISH) study. MATERIALS AND METHODS: Retrospective study was performed on 767 referred breast cancer cases over a period of five years. The HER2 IHC score (the initial and repeat test score) and the results of HER2 gene status by DDISH were retrieved from the histopathological reports. The agreement between initial IHC score with repeat test score was measured using Cohen Kappa. Chi square test analyzed the association between HER2 IHC score with its gene status by DDISH. RESULTS: The concordance of HER2 IHC score between the initial and repeat test were 52.7% and 89.4% for IHC score 2+ and 3+ respectively. There was moderate agreement of HER2 IHC score between the initial and repeat test score (ϰ = 0.526, p<0.001). A significant association noted between HER2 IHC score with its gene status by DDISH (p<0.001). Only 56 out of 207 cases (27.1%) with 2+ IHC score showed HER2 gene amplification while the majority of cases with 3+ IHC score were gene-amplified (446 out of 451, 98.9%). CONCLUSION: ISH study should be done in all IHC-equivocal cases (2+) to select patient for targeted therapy. Gene amplification must also be confirmed in IHC-positive cases (3+) to prevent from giving non-effective treatment with possible adverse effects to patient with non-amplified HER2 gene.

AB - INTRODUCTION: Evaluation of HER2 status in breast cancer using immunohistochemistry (IHC) and in-situ-hybridisation (ISH) study is important to establish prognosis and to select patient for targeted therapy. OBJECTIVE: The study aims to determine the concordance between HER2 protein IHC score and its gene status by dual-colour dual-hapten in-situ-hybridization (DDISH) study. MATERIALS AND METHODS: Retrospective study was performed on 767 referred breast cancer cases over a period of five years. The HER2 IHC score (the initial and repeat test score) and the results of HER2 gene status by DDISH were retrieved from the histopathological reports. The agreement between initial IHC score with repeat test score was measured using Cohen Kappa. Chi square test analyzed the association between HER2 IHC score with its gene status by DDISH. RESULTS: The concordance of HER2 IHC score between the initial and repeat test were 52.7% and 89.4% for IHC score 2+ and 3+ respectively. There was moderate agreement of HER2 IHC score between the initial and repeat test score (ϰ = 0.526, p<0.001). A significant association noted between HER2 IHC score with its gene status by DDISH (p<0.001). Only 56 out of 207 cases (27.1%) with 2+ IHC score showed HER2 gene amplification while the majority of cases with 3+ IHC score were gene-amplified (446 out of 451, 98.9%). CONCLUSION: ISH study should be done in all IHC-equivocal cases (2+) to select patient for targeted therapy. Gene amplification must also be confirmed in IHC-positive cases (3+) to prevent from giving non-effective treatment with possible adverse effects to patient with non-amplified HER2 gene.

UR - http://www.scopus.com/inward/record.url?scp=85071470471&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071470471&partnerID=8YFLogxK

M3 - Article

VL - 41

SP - 133

EP - 138

JO - Malaysian Journal of Pathology

JF - Malaysian Journal of Pathology

SN - 0126-8635

IS - 2

ER -